You Position: Home > Paper
New strategies in therapy for inflammatory bowel disease
( views:313, downloads:130 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 22
- DOI:
- 10.3969/j.issn.1009-3079.2008.22.011
- Key Word:
- 炎症性肠病;生物制剂;上阶梯治疗;下阶梯治疗;自然病史
Abstract： 炎症性肠病(inflammatory bowel disease,IBD)的传统药物治疗存在很大的局限性.生物制剂带来的令人振奋的效果,引发了一场上阶梯(step-up)和下阶梯(top-down)治疗策略之间的较量.针对新发的难治性克罗恩病(crohn'Sdisease,CD)患者,最新研究显示,下阶梯(top-down)治疗较目前标准治疗在诱导和维持疾病缓解、促进黏膜愈合等方面均有明显优势,其可能改变疾病的自然病史.然而,仍有一些因素限制生物制剂作为一线治疗用于IBD患者.目前,如何摆放生物治疗的地位以获取最佳效益风险比成为IBD治疗的争论焦点.
- [1]Verkade HJ,Jaspers GJ,Rings EH,etc.Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease.[J].2006,12(9).
- [2]G, van Assche,S, Vermeire,P, Rutgeerts.Emerging biological treatments in inflammatory bowel diseases.[J].2007,53(3).
- [3]Honiball PJ,Bloomfield R,Mason D,etc.Certolizumab pegol for the treatment of Crohn's disease.[J].2007,357(3).
- [4]Baert F,van Assche G,D'Haens G.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.[J].2008,371(9613).
- [5]Hanauer SB,Colombel JF,Rachmilewitz D,etc.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.[J].2002,359(9317).
- [6]Van Assche G,Vermeire S,Rutgeerts P.Review article: Infliximab therapy for inflammatory bowel disease--seven years on.[J].2006,23(4).
- [7]Schreiber S,Khaliq-Kareemi M,Hanauer SB,etc.Maintenance therapy with certolizumab pegol for Crohn's disease.[J].2007,357(3).
- [8]Sandborn WJ.Initial combination therapy in early Crohn's disease.[J].2008,371(9613).
- [9]Armuzzi A,Danese S,Papa A,etc.Biological therapies for inflammatory bowel disease: research drives clinics.[J].2006,6(7).
- [10]van-Assche G,Rutgeerts P,Vermeire S.Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.[J].2007,25(1).
- [11]G, D'haens,S, Van Deventer,R, Van Hogezand,etc.Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.[J].1999,116.